Active Clinical Trials at OOS

All Clinical Trials

ASTX030-01

Tumor site:
Hematologic (MDS, CMML, AML)
Description:
A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Available at:
Notes:
Sponsor: Astex; NCT Number: NCT04256317

AVANZAR (D926NC00001)

Tumor site:
Lung
Description:
A Phase III, Randomized, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Available at:
Notes:
Sponsor: AstraZeneca; NCT Number: NCT05687266

BillionToOne

Tumor site:
Solid Tumors
Description:
Compare the clinical relevant biomarkers identified by a novel BillionToOne quantitative ctDNA somatic mutation profiling assay with clinically available comparable assays in patients with advanced stage solid tumors.
Available at:
Notes:
Study Sponsor: BillionToOne Inc.; IRB number: 20230250

Amplitude (67652000PCR3002)

Tumor site:
Prostate
Description:
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Available at:
Notes:
Sponsor: Janssen; NCT Number: NCT04497844

BDX-00146

Tumor site:
Lung
Description:
***Enrollment closing soon*** An Observational Study Assessing the Clinical Effectiveness of the VeriStrat® Test and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer (INSIGHT)
Available at:
Notes:
Sponsor: Biodesix Inc; NCT Number: NCT03289780

Bespoke 20-041-NCP

Tumor site:
Colorectal
Description:
***Enrollment closed*** An Observational Study of ctDNA Guided Therapy in Colorectal Cancer.
Available at:
Notes:
Sponsor: Natera Inc; NCT Number: NCT04264702

EQ132-201

Tumor site:
Breast
Description:
***Enrollment closed*** A Phase 2 Study to Evaluate the Safety and Efficacy of Lerociclib in Participants with Advanced Breast Cancer
Available at:
Notes:
Sponsor: EQRx, Inc; NCT Number: NCT05085002

INTRINSIC

Tumor site:
Colorectal Cancer
Description:
A Phase I/Ib global, multicenter, open-label umbrella study evaluating the safety and efficacy of targeted therapies in subpopulations of patients with metastatic colorectal cancer
Available at:
Notes:
Sponsor: Roche; NCT Number: NCT04929223

Mirati KRYSTAL 7

Tumor site:
Lung (NSCLC)
Description:
Phase 2 Trial of MRTX849 Plus Pembrolizumab for NSCLC With KRAS G12C Mutation (KRYSTAL-7)
Available at:
Notes:
Sponsor: Mirati Therapeutics Inc; NCT Numer: NCT04613596

VIKTORIA-1

Tumor site:
Breast
Description:
A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
Available at:
Notes:
Sponsor: Celcuity; NCT Number: NCT05501886
Page 1 of
Page: